Bladder cancer trials

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion Criteria 1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC). 2. Locally advanced unresectable or metastatic BTC…. Goal: The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jazz Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Gallium-68 FAPI PET/CT to see if it improves detection, staging, and restaging of biliary tract cancers compared with the standard FDG PET/CT. It is for adults 18 and older with suspected or confirmed biliary cancers, including gallbladder cancer, cholangiocarcinoma, or suspected recurrence after treatment. The study will assess how well FAPI detects primary tumors, lymph node involvement, and metastases and whether it changes clinical decisions or reduces the need for invasive procedures. Participants must give informed consent, and those with a concurrent malignancy are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a new intravesical MRI protocol that uses a contrast mixture placed into the bladder to help stage bladder cancer. It is for adults with a papillary bladder tumor scheduled for TURBT or adults with muscle-invasive bladder cancer planned for radical cystectomy. The study aims to see if this MRI method is safe and whether MRI findings correctly reflect tumor presence and how deeply the cancer invades the bladder wall, compared with the surgical pathology results. Two radiologists who don’t know the surgical results will review the MRI scans to determine the radiologic stage. Key exclusions include allergy to the contrast agents gadobutrol or ferumoxytol, severe claustrophobia, MRI-incompatible implants, known or suspected metastatic disease, pregnancy, active urinary tract infection, and urethral stricture.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers is being studied. Conditions: Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed…. Goal: International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer is being studied. Conditions: Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations +3 • Eligibility: Inclusion Criteria: * Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures * Able to understand and given…. Goal: Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC Phase/Status/Sponsor: Unknown phase; RECRUITING; Tyra Biosciences, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Johns Hopkins trial is currently recruiting and tests using MRI to guide gynecologic brachytherapy, comparing it with CT planning to see if MRI can better show the tumor and protect nearby healthy tissues. It is for adults with gynecologic cancers (cervix, uterus, vagina, vulva, or urethra) who are eligible for internal brachytherapy, including people who have had prior radiation or chemotherapy. Researchers want to learn if MRI-guided planning lowers the radiation dose to nearby organs and to find safe dose levels that minimize side effects, checking outcomes at 6 months, 1 year, and 2 years after treatment. Key exclusions include uncontrolled illness, very low white blood cell count (ANC < 500), or metal in the head or eyes; participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes is being studied. Conditions: Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms +76 • Eligibility: Inclusion Criteria: * Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study…. Goal: Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cedars-Sinai Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 is being studied. Conditions: Urothelial Carcinoma • Eligibility: Inclusion Criteria: Cohorts A and B * Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra * Participants…. Goal: This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests intravesical chemoablation with gemcitabine for adults with Ta low-grade bladder cancer. - It is a single-arm, prospective, open-label Phase 2 trial designed to see if this treatment is effective, safe, and tolerable. - Eligible participants are adults (18+) with Ta low-grade bladder cancer, either recurrent or primary, with up to five tumors and each no larger than 15 mm. - They must have negative high-grade cytology, no muscle-invasive disease or metastasis, and no intravesical therapy within the last year, UTUC, active infection, pregnancy, or HIV. - The treatment consists of six weekly intravesical gemcitabine instillations, and the trial will assess efficacy, safety, and tolerability.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests a multimodal AI model to predict how bladder cancer patients will respond to neoadjuvant treatment, using MRI images, digital pathology, and clinical/genomic data. It is for bladder cancer patients who are planned for neoadjuvant therapy and radical cystectomy and who have histopathologic confirmation. This observational study will build and internally validate the AI model and assess how well it generalizes across centers. About 130 patients will be enrolled; exclusions include missing imaging or pathology data, prior local or systemic treatments, and poor-quality images.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quebec Pancreas Cancer Study is being studied. Conditions: Pancreas Cancer, Pancreatic Cancer, Pancreas Neoplasm +8 • Eligibility: Inclusion Criteria: * Individual diagnosed with pancreatic cancer. * Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer, duodenal cancer, gallbladder cancer). * Individual diagnosed with…. Goal: The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families. Phase/Status/Sponsor: Unknown phase; RECRUITING; George Zogopoulos.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies is being studied. Conditions: Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer +4 • Eligibility: Inclusion Criteria: * Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol…. Goal: The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Celon Pharma SA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy is being studied. Conditions: Melanoma, Breast Cancer, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria * Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included…. Goal: The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests the safety of delivering nab-paclitaxel directly into the abdomen with pressurized intraperitoneal aerosolization (PIPAC) together with gemcitabine and cisplatin for biliary tract cancers that have spread to the peritoneum. - It is for adults with biliary tract cancer and visible peritoneal metastases who meet health criteria. - The study aims to learn about safety and how well the treatment works, including overall survival, progression-free survival, surgical outcomes after the PIPAC procedure, and patients’ quality of life and daily functioning. - Key exclusions include prior systemic therapy for advanced disease, substantial liver involvement, brain metastases, pregnancy, and other serious health conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests adding intravesical nadofaragene firadenovec to the standard neoadjuvant treatment (gemcitabine, cisplatin, and durvalumab) before radical cystectomy for muscle-invasive bladder cancer. - It is for adults with confirmed muscle-invasive bladder cancer who plan to have radical cystectomy and are eligible for the standard neoadjuvant therapy. - The study aims to assess safety and to see whether the gene therapy can improve cancer outcomes beyond the current treatment. - Key exclusions include very advanced disease (spread to lymph nodes or beyond), other active cancers, prior systemic therapy for muscle-invasive bladder cancer, recent systemic immunosuppressants, prior adenovirus-based treatments, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a combination of Iparomlimab and Tuvonralimab Injection (QL1706) with GemOX chemotherapy and lenvatinib as conversion therapy for initially potentially resectable intrahepatic cholangiocarcinoma and gallbladder cancer. - It is for adults (18 years and older) who have locally advanced or potentially resectable disease, have not had prior systemic therapy for biliary tract cancer, and have at least one measurable tumor. - The study aims to learn how well this treatment can convert tumors to a state where surgery might be possible and how safe it is. - Key exclusions include prior anticancer therapy, active autoimmune disease, HIV infection, uncontrolled heart disease, recent or active other cancers, and extensive liver metastases.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The LIVELONG trial tests whether adding locally ablative therapies to ongoing systemic cancer treatment benefits people with oligo-progressive gastrointestinal cancers. It includes adults with gastric/GEJ, small bowel, colorectal/appendiceal, biliary, hepatocellular carcinoma, or pancreatic/ampullary cancers who have up to five new or progressing metastases and can continue systemic therapy with at most a 30-day break for ablation. Participants will receive either stereotactic ablative radiotherapy or interventional radiology ablation in addition to their current systemic therapy, and will be followed to assess disease control at 3 months and time to treatment failure. The trial is a single-site, pragmatic phase 2 study at UC Davis; key exclusions include medical conditions that preclude ablative therapy, prior toxicities that would prohibit ablation, and progressing brain metastases.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether urine tumor DNA (utDNA) can help decide if people with non-muscle-invasive bladder cancer can have less-frequent cystoscopy surveillance. It targets adults with high-risk bladder cancer who have completed induction therapy (BCG or gemcitabine/docetaxel) and had a negative post-induction assessment. The researchers want to learn if utDNA can indicate recurrence risk and support de-intensified surveillance. Exclusions include high-risk NMIBC within the last 3 years, prior induction intravesical therapy, variant histology, or concurrent upper tract disease. The study is currently recruiting and is sponsored by Lahey Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests giving cisplatin-based chemotherapy before surgery (neoadjuvant chemotherapy) for upper tract urothelial cancer, which is cancer of the kidney lining or ureter. It is for adults with newly diagnosed UTUC that can be seen on imaging and who are planned for surgery and chemotherapy. The study aims to find out whether there are enough eligible patients in Canada to enroll in a trial of this pre-surgery approach. Key exclusions include metastatic or nodal disease, concurrent muscle-invasive bladder cancer, having only one kidney, and medical conditions that prevent cisplatin therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer is being studied. Conditions: Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer +1 • Eligibility: Inclusion Criteria: Age 18-75 years at time of enrollment; Histologically or cytologically confirmed advanced or metastatic biliary tract adenocarcinoma (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder carcinoma); Unresectable locally…. Goal: Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help patients live longer without their cancer getting worse. Phase/Status/Sponsor: Unknown phase; RECRUITING; First Affiliated Hospital of Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) is being studied. Conditions: NMIBC, MIBC, UTUC • Eligibility: Cohort I: Inclusion Criteria: * patients ≥18 years of age with full civil capacity at the time of signing the informed consent form; * patients who provide a…. Goal: This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or N+); cohort II was patients with non-muscle invasive bladder cancer (NMIBC) (including low-risk, intermediate-risk, and high-risk/very-high-risk); cohort III was patients with muscle-invasive bladder cancer (MIBC) to receive neoadjuvant therapy; and cohort IV was patients evaluated for complete response (CR) after standard trimodality therapy (TMT) treatment (i.e. patients with successful bladder preservation). Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking University First Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests adding tazemetostat to pembrolizumab for adults with locally advanced or metastatic urothelial carcinoma (cisplatin-resistant or platinum-ineligible). - The main goal is to find a safe dose for the combination and to see how well it works, including response rate, progression-free survival, and immune-related tumor responses. - The trial also includes correlative studies using tissue and blood to learn which patients may respond. - Key exclusions include prior PD-L1 or EZH2 inhibitors, active brain metastases (unless previously treated and stable), pregnancy or breastfeeding, and certain uncontrolled illnesses or recent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether body composition problems such as sarcopenia, myosteatosis, obesity, and poor nutrition influence the risk of recurrence and progression in adults with non-muscle-invasive bladder cancer (NMIBC). - It is for adults with NMIBC who are scheduled for transurethral resection of bladder tumor (TURBT) and will be followed with standard surveillance. - Researchers will use sarcopenia and nutritional screening, body measurements (BMI, waist), blood tests (albumin, testosterone), and CT scans to assess muscle mass and density, to see if these factors help predict recurrence or progression and improve risk stratification. - Eligibility includes adults 18+ with NMIBC (Ta, T1, or CIS) planned for TURBT and able to undergo CT imaging and consent; key exclusions are low-risk NMIBC, muscle-invasive bladder cancer, life expectancy under 3 months, CT contraindications, or inability to follow up.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study is being studied. Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder +1 • Eligibility: Inclusion Criteria: 1. Age ≥18 years; sex: all; signed written informed consent by the participant or legally authorised representative. 2. Histologically confirmed high-risk non-muscle-invasive bladder cancer (HR-NMIBC), defined…. Goal: This open-label, randomised, multicentre, phase 2 study (OHAI-NMIBC-01) compares toripalimab plus sequential intravesical gemcitabine followed by mitomycin C (GEM→MMC) with toripalimab alone in adults with BCG-unresponsive or BCG-intolerant high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Two prespecified cohorts are analysed: (1) CIS cohort (CIS with/without Ta/T1) and (2) non-CIS cohort (high-risk Ta/T1 without CIS). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; First Affiliated Hospital of Wenzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Researchers are testing FL115 placed in the bladder, either alone or with intravesical BCG, in adults with non-muscle invasive bladder cancer that is BCG-unresponsive (high-grade Ta/T1 or CIS). The trial will evaluate safety and tolerability and determine the recommended phase 2 dose of FL115 when used with BCG, plus look at early signs of effectiveness. It has three parts: FL115 monotherapy dose escalation, FL115 with BCG dose escalation, and FL115 with BCG cohort expansion. Eligible participants are adults 18+ with BCG-unresponsive NMIBC who are not candidates for radical cystectomy; key exclusions include prior IL-2 or IL-15 agonist therapy, recent NMIBC treatments or active infections, autoimmune disease requiring systemic immunosuppressants, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether combining bile-based molecular testing with standard biliary brush cytology/biopsy can improve detection of malignant biliary strictures. It is for adults aged 18–90 who have indeterminate biliary strictures and have undergone ERCP with biliary biopsy and/or brush cytology. Researchers will collect bile and screen for molecular markers using multi-omics to develop and validate a bile-based diagnostic model. Exclusions include coagulation disorders, pregnancy, other cancers not related to biliary strictures, or those who decline participation. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This open-label, phase 1b, multi-arm, biomarker-directed trial is for people with metastatic muscle-invasive bladder cancer that progressed after prior treatment; the study is active but not recruiting. - It uses several modules (A–G) to test MEDI4736 (durvalumab) with different partner drugs, or alone, with patients grouped by specific tumor genetic alterations (e.g., FGFR alterations, HRR gene mutations, or cell-cycle changes). - The aim is to learn about safety and tolerability, how the drugs behave in the body (pharmacokinetics), and early anti-tumor activity to guide future testing. - Key exclusions include recent systemic cancer therapy or immunotherapy, active infections, autoimmune disease, brain metastases, and certain heart/liver problems; some modules also restrict prior exposure to certain drugs or require contraception.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests the safety, tolerability, and potential effectiveness of giving durvalumab together with BCG (induction and maintenance) in adults with high-risk non-muscle-invasive bladder cancer who have not previously received BCG. - It targets adults in the United States whose high-risk NMIBC has been completely removed by TURBT and is confined to the lining of the bladder (Ta/T1). - The study is open-label and single-arm and aims to learn whether this combination can be safely given and whether it can improve cancer control during about two years of treatment, plus safety and survival follow-up. - Key exclusions include muscle-invasive or metastatic disease, active infections or autoimmune disorders, prior systemic immunotherapy, pregnancy, and certain other cancers or immunosuppressive conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The Multicentric Prospective T1 Urinary Bladder Cancer Registry is a multicenter, prospective study testing therapy failure rates and factors that affect outcomes in patients with primary T1 bladder cancer treated by transurethral resection. - It will recruit patients from international urology centers who have a confirmed primary T1 tumor, no metastasis, and who consent to central pathology review and follow-up. - The study will compare local pathology assessments with a central expert review to measure accuracy and inter-observer variability, and will analyze features like lymphovascular invasion, variant histology, and CIS to help develop a risk-stratification tool for guiding treatment decisions. - Exclusions include prior bladder cancer, upstaging to muscle-invasive disease at second TURB, contraindications to surgery, poor performance status, life expectancy under one year, pregnancy, or history of upper urinary tract urothelial cancer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors is being studied. Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer +5 • Eligibility: Inclusion Criteria: * diagnosed with any of the following cancers \[Stage I-III\]: breast, prostate, urinary bladder, and endometrial in the past 6 months; * being treated for cancer…. Goal: The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed better than those who receive usual care. This study focuses on "complex" cancer survivors who have higher CVD risk when diagnosed with cancer because they also have had a diagnosis of 1 or more chronic conditions (e.g., hypertension, diabetes, and/or hyperlipidemia) requiring medication management. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a phase 2, single-arm, open-label trial testing adjuvant nivolumab after chemoradiation for localized muscle-invasive bladder cancer. - It targets adults whose bladder cancer invades the muscle (stages T2-4, N0 or N+, M0 or T1 with N+) who are not candidates for radical cystectomy. - The study aims to learn the rate of failure-free survival 2 years after the start of chemoradiation when nivolumab is added after treatment. - Key exclusions include distant metastases outside the radiation field, active autoimmune disease, HIV or active hepatitis B/C, pregnancy or contraception noncompliance, and other active cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) is being studied. Conditions: Bladder Cancer, Prostate Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult subjects (age ≥ 22 years) as required by local law 2. Subject has been indicated for a radical prostatectomy, radical cystectomy, or nephrectomy (partial…. Goal: This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Medtronic - MITG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a bladder-preservation plan for muscle-invasive bladder cancer that uses immunotherapy before surgery, followed by TURBT to remove any remaining tumor and then radiation therapy with more immunotherapy. It is for adults with muscle-invasive bladder cancer (cT2–T4aN0M0) who are candidates for bladder-sparing treatment and have a good performance status. The study aims to learn how often this approach leads to a complete cancer response in the removed tissue, lowers the cancer stage, preserves the bladder, and affects survival, as well as safety, and it will collect tumor tissue to study genetic changes and biomarkers. Exclusion criteria include prior anti-PD-1/PD-L1 therapy (except BCG), cancer in situ, active infections, autoimmune disease requiring systemic therapy, end-stage renal disease, pregnancy, and other serious illnesses. The trial is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether Comprehensive Geriatric Assessment (CGA) with tailored perioperative care can reduce postoperative morbidity after major liver resection or pancreaticoduodenectomy for cancer in older adults. - It is for people aged 70 and older with hepatobiliary or pancreatic cancers who need these surgeries. - The study aims to learn if CGA can lower complications and improve quality of life after surgery. - Exclusions include not having access to the French health system, inability to consent, participation in a double-blind randomized trial, or being legally protected.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The ANTARES study is testing whether nivolumab, a PD-1 blocker, can work in people with advanced or metastatic rare tumors that express PD-L1 (CPS ≥ 10), regardless of tumor type. It is a phase II basket trial, enrolling adults whose cancers have higher PD-L1 expression after standard treatments have failed. Treatment can last up to 12 months, and researchers will look at objective responses, progression-free survival, and biomarkers like PD-L1, ctDNA, and microvesicles. Exclusions include prior immunotherapy, pregnancy or breastfeeding, active infection, autoimmune disease (with limited exceptions), and uncontrolled CNS metastases, among other health criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of COVID-19 on GU Disease is being studied. Conditions: COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions • Eligibility: Inclusion Criteria: * Subjects must be men and women 40 years of age or older * Subjects at risk or with GU cancer (Prostate, Bladder, Kidney) * Subjects…. Goal: The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Icahn School of Medicine at Mount Sinai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer is being studied. Conditions: Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma +7 • Eligibility: Inclusion Criteria: * Pathologically confirmed biliary tract cancer, having received at least 1 prior line of systemic therapy, and received no more than 2 prior lines of therapy…. Goal: This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA is being studied. Conditions: Bladder Cancer Recurrence, BPH (Benign Prostatic Hyperplasia), Bladder Cancer • Eligibility: Inclusion Criteria: * Males aged 40 - 65 year * First diagnosis of bladder neoplasm less than 4 cm, confined in urinary bladder * Prostate volume \> 40…. Goal: The rationale of my study is that studies have shown that between 50% and 70% of patients treated with trans-urethral bladder tumor resection (TURBT) alone for NMIBC have recurrence with stage and grade progression in 10% to 15% and because of this theoretical danger of tumor cell implantation, many urologists avoid simultaneous trans-urethral prostate resection (TURP) and TURBT due to fear of implantation of tumor cells in the denuded areas of the resected prostate and prefer to perform a separate procedure for each pathological condition. However, others observed no deleterious effects of simultaneous TURBT and TURP. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Allama Iqbal Medical College.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests NGM438 as a standalone treatment and in combination with pembrolizumab for advanced or metastatic solid tumors, to learn about safety and potential effectiveness. It targets adults whose cancer has progressed after other therapies or who could not tolerate them. Eligible participants need adequate bone marrow, kidney, and liver function and a performance status of 0 or 1. They must have recovered from prior treatment side effects to baseline or to CTCAE Grade 1. A key exclusion is prior treatment targeting LAIR1.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is an observational, long-term study of adults with malignant hepatobiliary tumors to observe how they respond to treatment in real-world care. - Researchers will collect a wide range of data—clinical information, photos of patients’ faces, measures of strength and nutrition, blood, stool, and tumor tissue—and use multi-omics testing to find markers. - The goal is to identify prognostic markers and potential therapeutic targets to help predict treatment response and guide personalized care. - Eligible participants are adults with malignant hepatobiliary tumors who are or will be treated; key exclusions include pregnancy, serious systemic diseases, mental health issues or poor compliance, unwillingness to participate, or an estimated survival under one month.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study is being studied. Conditions: Head and Neck Cancer, Melanoma, Breast Cancer +4 • Eligibility: Inclusion Criteria: 1. Male or female aged ≥ 18 and ≤ 75 years; 2. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard…. Goal: This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Fengxian District Central Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is being studied. Conditions: Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer +12 • Eligibility: Inclusion criteria: * verified peritoneal metastasis * colorectal cancer * ovarian cancer * gastric cancer * appendical cancer * pseudomyxoma peritonei * malignant mesothelioma * pancreatic cancer *…. Goal: Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases. Indication is decided by the treating physician. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sabine Rhode.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors is being studied. Conditions: Hepatocellular Carcinoma, Renal Cell Carcinoma, Bladder Cancer +3 • Eligibility: Inclusion Criteria: * Participantswith treatment-refractory advanced hepatocellular carcinoma, renal cell carcinoma,bladder cancer,colorectal cancer,non-small-cell lung cancer,breast cancer and other solid cancers. * Age 18 to 75 years. * Willing…. Goal: Background: Combinations of dendritic and cytokine-induced killer cell (D-CIK) based adoptive immunotherapy and anti-PD-1 antibody may enhance the immune response and stop cancer cells from growing. Objective: Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and anti-PD-1 antibody in patients with treatment-refractory solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase II clinical trial testing liposomal doxorubicin as a treatment for liver or bile duct cancers. It is for adults 18 and older with histologically confirmed cancers such as hepatocellular carcinoma, cholangiocarcinoma, or gallbladder cancer, with disease that can be measured or evaluated by imaging. The study aims to learn how well the treatment works (response rate) and what side effects or toxicity may occur. Eligibility notes include no pregnancy or nursing, no egg allergy, bilirubin under 3 mg/dL, no severe cirrhosis, adequate kidney and heart function, no prior doxorubicin, and at least 4 weeks since prior chemotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests peposertib together with avelumab and hypofractionated radiation therapy in adults with advanced or metastatic solid tumors and hepatobiliary cancers. - It aims to find a safe dose and assess how well this combination works, with Phase II focusing on hepatobiliary tumors and comparing against avelumab plus radiation alone by measuring objective response rate. - The study will also look at how the drugs are processed in the body and collect biomarker data to understand who may respond. - Eligibility notes include that Phase I excludes prior immune checkpoint therapy, while Phase II has some allowed prior checkpoint exposure under specific conditions; pregnancy is not allowed and certain autoimmune or CNS conditions exclude participation. - The study status is currently suspended.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection is being studied. Conditions: Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma +1 • Eligibility: Inclusion Criteria: 1. Male or female, age\> 18 years old, and \<75 years old. 2. Diagnosis is gallbladder cancer or biliary adenocarcinoma via pathological histology. 3. Patients have…. Goal: The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration is being studied. Conditions: Gallbladder Cancer • Eligibility: Inclusion Criteria: * Adults with normal renal function at the start i.e. eGFR\>60, Performance status 0 and 1, controlled nausea and vomiting at baseline. * ECOG performance status…. Goal: This is an open label study for any patients with a bile duct cancer or gallbladder cancer, who will be treated with gemcitabine and cisplatin chemotherapy (the ABC02 regime). Patients recruited onto this study will have a reduction of their hydration time and be given Akynzeo as an anti-sickness drug, to assess tolerability compared to the current standard of care. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Imperial College Healthcare NHS Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Two-in-one Covered and Uncovered Metal Stent is being studied. Conditions: Extrahepatic Bile Duct Cancer, Pancreatic Cancer, Lymph Node Metastases +1 • Eligibility: Inclusion Criteria: ㆍMalignant biliary obstruction, 2 cm distal to the hilum ㆍNot eligible for curative surgical resection owing to metastasis, locally advanced stage, or high operation risk ㆍEastern…. Goal: Endoscopic placement of a self-expandable metal stent (SEMS) is the principle method for palliation of inoperable malignant distal biliary obstruction. However, none of bare, covered, and anti-reflux metal stent alone constantly demonstrated superiority over the others in the stent patency. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Ajou University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Role of Different Imaging Methods in the Diagnosis of Gallbladder Polyps is being studied. Conditions: Polyp of Gallbladder • Eligibility: Inclusion Criteria: * All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US. Exclusion Criteria: * Gallbladder polyp with a diameter less than…. Goal: This prospective cohort study is designed to investigate and to compare the diagnostic performance of contrast-enhanced ultrasonography (CEUS) and multidetector computed tomography (CT) for gallbladder cholesterol polyps, adenoma and gallbladder cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an early-phase, open-label study testing a drug called EOC317 in Chinese adults with advanced solid tumors. It uses a 3+3 dose-escalation design to assess safety, tolerability, and how the drug behaves in the body, with doses from 5 to 60 mg to identify the maximum tolerated dose and a recommended dose for expansion. There is a dose-expansion phase to further study safety and early pharmacodynamic effects of the chosen dose in patients with advanced solid tumors, including urothelial cancer, cholangiocarcinoma, hepatocellular carcinoma, or other FGFR-altered tumors. Key exclusions include prior FGFR-targeted therapy, significant cardiovascular, liver, or kidney disease, active infection or certain CNS issues, pregnancy, and the inability to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System is being studied. Conditions: Esophageal Cancer, Gastric Cancer, Pancreatic Cancer +3 • Eligibility: Inclusion Criteria: 1. Patient with Her2-positive neoplasms of digestive system: IHC 3+ 2. Clinical staging: Phase III or above 3. Ages: \< 65 4. Expected survival time: \>…. Goal: This phase I trial is to investigate the safety and the possible side effects of bi-specific antibody armed T-cell therapy when given together with low-dose IL-2 in treating patients with Her2-positive neoplasms of digestive system. Expanded autologues T cells that have been coated with bi-specific antibodies, such as anti-CD3 and anti-human epidermal growth factor receptor 2 (HER2), may stimulate the immune system in different ways and stop tumor cells from growing. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Yi Miao.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers is being studied. Conditions: Urothelial Carcinoma, Head and Neck Cancer, Melanoma +1 • Eligibility: Inclusion Criteria: 1. Subject is ≥18 to ≤75 years of age at the time of signing the study informed consent. 2. Subject has histologically confirmed diagnosis of any…. Goal: This Phase 1 study is designed as a cell dose escalation trial in HLA-A\*02:01 and HLA-A\*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Phase/Status/Sponsor: Unknown phase; COMPLETED; Adaptimmune.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Influence of Anesthesia Methods on CTCs in TURBT Patients is being studied. Conditions: Bladder Cancer • Eligibility: Inclusion Criteria: 1. .≤18 Age ≤85，ASAI-III. 2. .Patients with primary bladder cancer of Stage T1 to T4, who are scheduled for transurethral resection of bladder tumor. 3. .Written…. Goal: Multiple lines of evidence have shown that anesthesia method is associated with long-term outcomes in patients undergoing surgery due to cancers, including lung, breast, prostate, and bladder cancer, etc. Circulating tumor cells (CTCs) have been validated as prognostic biomarkers of a number of cancers. Phase/Status/Sponsor: Unknown phase; UNKNOWN; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether cell-free nucleic acids in blood, plus the gut microbiome in stool and metabolites in urine, are related to pancreatic cancer and biliary tract cancer. - It includes adults diagnosed with pancreatic cancer or biliary tract cancer who have not yet started treatment. - Researchers aim to see if these measurements can help with diagnosis, treatment decisions, and predicting prognosis for these cancers. - Exclusion criteria include inability to consent, certain sample handling or quality issues, samples from deceased patients, samples from other cancer sites, and protections for vulnerable groups like pregnant people or minors.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. is being studied. Conditions: Solid Tumor, Adult • Eligibility: Inclusion Criteria: Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder…. Goal: T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumor-infiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. Phase/Status/Sponsor: Unknown phase; UNKNOWN; TScan Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study compares two methods of placing bilateral metal stents for malignant hilar biliary obstruction: side-by-side stenting (6 mm) versus stent-in-stent (10 mm). - It is for adults with hilar malignant biliary obstruction who require biliary drainage. - The trial aims to learn which method provides better stent patency and longer survival, and to compare safety between the approaches. - Key exclusions include operable disease, non-hilar obstruction, duodenal obstruction, other cancers, uncontrolled infection, poor performance status (ECOG ≥3), no informed consent, or failed endoscopic access.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma is being studied. Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer • Eligibility: Inclusion Criteria: * • Chinese； * Stable vital signs, KPS≥60; * Patients have a diagnosis of advanced or recurrent metastatic extrahepatic cholangiocarcinoma or gallbladder carcinoma by histopathology or…. Goal: The purpose of this study is to evaluate the feasibility, efficacy and safety of FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Jiao Tong University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Brightline-2 trial tests whether brigimadlin (BI 907828) helps adults with advanced cancer of the biliary tract, pancreas, lung, or bladder. It’s for people whose cancer has not responded to standard treatment or for whom no standard treatment exists. Brigimadlin is taken as a tablet every 3 weeks, with regular visits to monitor tumor size and safety. Eligibility requires specific tumor biology (MDM2 amplification or TP53 wild-type) confirmed by tissue testing and measurable disease with good performance status. Key exclusions include prior brigimadlin or other MDM2/MDMX-p53 drugs, risk of significant bleeding, or conditions that could make participation unsafe. The study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tested whether tumor tissue and blood can identify biomarkers that predict how advanced biliary tract cancer responds to a chemotherapy combination of gemcitabine, cisplatin, and nab-paclitaxel. It enrolled adults with biliary tract cancer that is unresectable, metastatic, or recurrent, who planned to receive the triplet chemotherapy after tumor sequencing. Researchers used biopsy samples for in-house sequencing and collected blood over time to study cell-free DNA and circulating tumor cells and their relation to response and progression. Eligibility required measurable disease and good performance status, with key exclusions including uncontrolled illness, prior palliative chemotherapy for BTC, and dementia or other conditions affecting consent. Status: COMPLETED; Sponsor: CHA University; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study is being studied. Conditions: Biliary Tract Carcinoma • Eligibility: Inclusion Criteria * Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer) * Has measurable disease based…. Goal: In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS). Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Project HERO: Health Empowerment & Recovery Outcomes is being studied. Conditions: Prostate Cancer, Bladder Cancer, Kidney Cancer +6 • Eligibility: Inclusion Criteria: * Age ≥ 55 years * Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on…. Goal: Project HERO is a 12-week study of the efficacy of Body Mind Training (BMT, i.e. Tai Chi and Qigong in this project) for reducing fatigue in male cancer survivors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib is being studied. Conditions: Esophageal Adenocarcinoma, Esophagus SCC, Cholangiocarcinoma +2 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old 2. Female or male 3. ECOG performance status ≤ 1 4. Life expectancy of greater than 12 weeks 5. Must…. Goal: Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jules Bordet Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tested a combination of capecitabine with epirubicin and carboplatin in people with progressive, unresectable, or metastatic cancer. It aimed to determine the recommended dose of capecitabine in this Phase I trial and to assess the regimen’s side effects. It also looked at how the drugs are processed in the body, possible genetic factors related to toxicity, and whether the treatment shows antitumor activity. Eligible participants included patients whose cancer progressed after standard therapy or unresectable disease, with exclusions such as prior high cumulative doxorubicin exposure and active infections requiring IV antibiotics. The trial is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma is being studied. Conditions: Urothelial Carcinoma, Bladder Cancer • Eligibility: Inclusion Criteria: 1. Urothelial carcinoma group: * Any male or female patient aged 18 or older. * Able to provide urine specimen (100ml for both first void and…. Goal: Clinical trial to evaluate the performance characteristics(sensitivity and specificity) of AnchorDx's urine DNA methylation/somatic mutation profiling assay for detecting urothelial carcinoma compared to pathology in patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; AnchorDx Medical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers is being studied. Conditions: Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma +8 • Eligibility: Inclusion Criteria: 1. Subjects must have histologic confirmation of advanced, biopsy-accessible, measurable cancers of the following histologies: * Non-viral-associated head and neck squamous cell carcinoma (HNSCC) or human…. Goal: This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ludwig Institute for Cancer Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety Study of MGA271 in Refractory Cancer is being studied. Conditions: Prostate Cancer, Melanoma, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer, non-small cell lung cancer) or melanoma…. Goal: The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; MacroGenics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) is being studied. Conditions: Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer +2 • Eligibility: * INCLUSION CRITERIA: * Patients must have histopathological confirmation of biliary tract carcinoma (BTC) by the Laboratory of Pathology of the National Cancer Institute (NCI) prior to entering…. Goal: Background: Biliary tract cancers are rare but they are serious. Researchers want to see if a certain drug helps the immune system fight cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase I trial tests an intrapleural gene therapy called BG00001, which delivers the interferon-beta gene into the pleural space to treat malignant pleural mesothelioma or malignant pleural effusions. It is for adults 18 and older whose disease has progressed after standard therapy and whose pleural space can be accessed with a chest catheter. The study aims to find a safe dose, determine the maximum tolerated dose, assess gene transfer and interferon-beta expression, monitor immune responses, and look for early signs of tumor effect. Key exclusions include HIV positivity, active brain metastases (unless previously treated with no active growth), ongoing immunosuppressive therapy, pregnancy, and other active cancers within the past 5 years (with limited exceptions for certain skin cancers or successfully treated localized bladder or prostate cancer).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether ondansetron works better for preventing vomiting when given with dexamethasone versus with a placebo in cancer patients receiving radiation therapy to the upper abdomen. - It is a randomized, double-blind, placebo-controlled, multicenter study. - It looks at how well the two regimens prevent vomiting and nausea, their side effects, and impact on quality of life. - Eligible participants are people aged 16 or older with cancer planned for upper abdominal radiotherapy (at least 2,000 cGy in 15+ fractions) who have not had significant vomiting recently; major exclusions include liver problems, active peptic ulcers, concurrent cytotoxic therapy or other steroids, and a history of adverse reactions to antiemetic drugs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Irinotecan and Capecitabine in Treating Patients With Solid Tumors is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed solid tumors, including but not limited to breast, gastrointestinal, and unknown primary cancer that is refractory to standard therapy or for which no standard…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Montefiore Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed gallbladder cancer or cholangiocarcinoma * Locally advanced or metastatic disease that is unresectable * Eligible subtypes: * Adenocarcinoma, intestinal type *…. Goal: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer is being studied. Conditions: Cancer • Eligibility: Inclusion criteria: * Solid cancer with evidence of metastases * Receiving treatment at Beth Israel Deaconess Medical Center (BIDMC) * Must reside ≤ 25 miles from BIDMC Exclusion…. Goal: RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Beth Israel Deaconess Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer +3 • Eligibility: Inclusion Criteria: * Only advanced carcinomas defined as unresectable or metastatic that are histologically or cytologically confirmed to be biliary tract, pancreas, duodenal, or ampullary carcinomas will be…. Goal: RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Vanderbilt-Ingram Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether giving gemcitabine hydrochloride with oxaliplatin after surgery helps people with biliary tract cancer live longer without the cancer returning, compared with observation alone. It is for adults whose biliary tract cancer was surgically removed (within about 4 to 13 weeks) and is not metastatic. The study mainly looks at disease-free survival and quality of life, and also checks overall survival and treatment toxicity. Exclusions include HIV infection, pregnancy, and other serious illnesses or contraindications to the chemotherapy drugs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Internet-based System for Cancer Patients to Self-report Toxicity is being studied. Conditions: Cervical Cancer, Lung Cancer, Prostate Cancer +4 • Eligibility: Inclusion Criteria: * Age \>18 years * Diagnosis of gynecologic (ovarian; cervical; uterine; primary peritoneal), lung (non-small cell; small cell), gastrointestinal (colorectal, rectal, gastric, esophageal, GI neuroendocrine, small…. Goal: Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath. These symptoms may be due to the cancer itself, or due to treatments like chemotherapy drugs or radiation therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed unresectable or metastatic biliary tract carcinoma (extrahepatic, intrahepatic, or ampulla of Vater) or gallbladder carcinoma Not amenable to combined chemotherapy and radiotherapy CNS metastases…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer • Eligibility: * One of the following histologically or cytologically confirmed cancers not amenable to treatment with combined chemotherapy and radiotherapy: * Biliary tract (intrahepatic, extrahepatic, or ampulla of Vater)…. Goal: RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors is being studied. Conditions: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor • Eligibility: Inclusion criteria. * Patient must understand nature of trial and provide a signed and dated, written informed consent form prior to study specific procedures, sampling and analyses. If…. Goal: This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312. This is a multicentre study with sites in the United States and United Kingdom. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer is being studied. Conditions: Gallbladder Cancer • Eligibility: DISEASE CHARACTERISTICS: Histologically or cytologically proven gallbladder or bile duct carcinoma with metastatic or recurrent disease deemed unresectable and not considered a candidate for potentially curative therapy Measurable…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with advanced gallbladder or bile duct cancer that cannot be removed surgically. Phase/Status/Sponsor: Unknown phase; COMPLETED; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 is being studied. Conditions: Advanced Malignancies • Eligibility: Inclusion Criteria: Among other criteria, patients must meet all of the following conditions to be eligible to be in the study: 1. 18 years of age or older.…. Goal: The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein. Phase/Status/Sponsor: Unknown phase; COMPLETED; Celldex Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed cancer, including, but not limited to, the following: * Melanoma * Breast cancer * Invasive squamous cell cancer * Other cancers…. Goal: RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. Phase/Status/Sponsor: Unknown phase; COMPLETED; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests adding motexafin gadolinium to radiation therapy for adults with bile duct, gallbladder, or pancreatic cancer that cannot be removed with surgery. - It is a multicenter Phase I dose-escalation trial to learn about safety and toxicity, how the drug behaves in the body, and the maximum tolerated dose. - The researchers will also look at how the tumor takes up the drug (via MRI) and whether tumors show a radiologic response. - Eligible participants are adults with locally advanced unresectable disease (limited metastases may be allowed if palliation with radiotherapy is needed); key exclusions include pregnancy, G6PD deficiency, significant liver or kidney problems, active infection, and porphyria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer is being studied. Conditions: Neoplasms • Eligibility: Inclusion Criteria * Age ≥ 18 years at time of consent. * Histologically or cytologically confirmed diagnosis of one of the following: adenocarcinoma of the breast, ovary, or…. Goal: This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist. OGX-427 is an antisense product that inhibits expression of one of the heat shock proteins. Phase/Status/Sponsor: Unknown phase; COMPLETED; Achieve Life Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following advanced cancers: * Stage IIIB or IV non-small cell lung cancer * Extensive stage small cell lung cancer *…. Goal: RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a standard care program in improving end-of-life care in patients with advanced lung , gastrointestinal, genitourinary, or breast cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Dartmouth-Hitchcock Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors is being studied. Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor, including the following tumor types: * Breast cancer * Non-small cell lung cancer * Prostate cancer * Bladder cancer * Gastroesophageal…. Goal: RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed metastatic, locally advanced, or recurrent cancer of the liver (hepatoma), bile duct, or gallbladder (cholangiocarcinoma) Bidimensionally measurable disease The following are not considered measurable…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer is being studied. Conditions: Cholangiocarcinoma, Gallbladder Cancer • Eligibility: 1. Patients must have biopsy-proven locally-advanced, metastatic or recurrent adenocarcinoma of the biliary ducts or gallbladder. 2. Patients must have measurable disease. 3. Patients must be 18 years…. Goal: To determine the activity of gemcitabine combined with carboplatin in the treatment of patients with metastatic or recurrent cholangiocarcinoma or gallbladder cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer is being studied. Conditions: Anal Cancer, Colorectal Cancer, Esophageal Cancer +7 • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed metastatic gastrointestinal carcinoma Measurable disease No CNS metastases No obstruction or partial obstruction of GI tract No obstruction of genitourinary tract PATIENT CHARACTERISTICS: Age:…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer is being studied. Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer +9 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Histologically confirmed advanced primary or malignant solid tumor refractory to standard therapy or for which no curative standard…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer +1 • Eligibility: DISEASE CHARACTERISTICS: Histologically proven malignant bile duct obstruction with obstructive jaundice Primary carcinoma of bile duct, gallbladder, or pancreas OR Metastatic bile duct disease Successful insertion of a…. Goal: RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests giving recombinant human interleukin-12 (rhIL-12) into the abdominal space to treat adults with chemotherapy-refractory ovarian cancer or other diffuse abdominal cancers, using escalating doses to find a safe level. It is a Phase I, dose-escalation, multicenter trial designed to determine safety and the maximum tolerated dose, and to study how rhIL-12 affects the immune system and tumor biology, with weekly infusions for 9 weeks (and possibly extra weeks if there is a response). Eligible participants are adults 18 and older with measurable intraabdominal cancer that is refractory to chemotherapy and has adequate organ function and performance status; key exclusions include progressive brain metastases, pregnancy, active infection, autoimmune disease, and other major illnesses. The trial has completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interleukin-12 in Treating Patients With Cancer in the Abdomen is being studied. Conditions: Anal Cancer, Colorectal Cancer, Gallbladder Cancer +2 • Eligibility: DISEASE CHARACTERISTICS: Histologically or cytologically confirmed Mullerian carcinoma (ovarian epithelial or peritoneal carcinoma) (closed to accrual as of 8/23/01) OR Gastrointestinal cancer with abdominal carcinomatosis OR Peritoneal mesothelioma…. Goal: RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a three-drug chemotherapy combo—gemcitabine, fluorouracil, and leucovorin—for people with recurrent, refractory, or metastatic solid tumors or lymphomas. - It is a Phase I dose-escalation study to assess safety, how the drugs behave in the body (including steady-state levels), and any antitumor activity. - Participants are adults (18+) with cancers that failed standard therapy or for which none exists; key exclusions include leukemia, CNS metastases, prior gemcitabine therapy, and HIV infection. - The study was sponsored by the NIH Clinical Center and is listed as completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder is being studied. Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed cholangiocarcinoma or carcinoma of the gallbladder * Advanced and/or inoperable disease * Measurable disease * At least 1 unidimensionally measurable lesion…. Goal: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Roswell Park Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Therapy in Treating Patients With Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven CEA expressing adenocarcinoma * Serum CEA levels greater than 10 ng/mL * Failed standard therapy * Measurable disease PATIENT CHARACTERISTICS: Age: * 18…. Goal: RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have cancer that has not responded to previous therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Roger Williams Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase I trial tests intraperitoneal oxaliplatin (injected into the abdomen), with or without intraperitoneal floxuridine and leucovorin, in people whose cancer is largely confined to the peritoneal cavity. - It aims to find the maximum tolerated dose, identify dose-limiting toxicities, and study how the drugs behave in the body (pharmacokinetics). - Eligible participants are adults 18+ with metastatic or unresectable cancer largely confined to the peritoneum, no known brain metastases, and adequate organ function; key exclusions include allergy to platinum drugs, pregnancy, active infection, and other uncontrolled illnesses. - The trial status is completed and it was sponsored by Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed advanced malignancy involving the peritoneal cavity, excluding leukemia and lymphoma Patients with ovarian cancer must have received prior standard therapy Predominantly small tumor metastases…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced cancer of the peritoneal cavity. Phase/Status/Sponsor: Unknown phase; COMPLETED; NYU Langone Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer is being studied. Conditions: Breast Cancer, Colorectal Cancer, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria 1. Patients must have incurable, metastatic or unresectable locally advanced breast, colorectal, pancreatic, bladder or ovarian cancer with measurable or evaluable-only disease. Locally advanced breast cancer…. Goal: This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. Phase/Status/Sponsor: Unknown phase; COMPLETED; Celldex Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests TT-00420 (Tinengotinib) as a tablet given alone and in combination for adults with advanced solid tumors. It has three arms: Arm A tests TT-00420 alone in various advanced cancers; Arm B combines TT-00420 with atezolizumab for advanced biliary tract cancer; Arm C combines TT-00420 with nab-paclitaxel for advanced triple-negative breast cancer. The study is a Phase Ib/II, multicenter, open-label trial that aims to find a safe and tolerable dose for the next phase and then evaluate preliminary efficacy in each arm. Eligibility includes adults 18 or older with measurable disease and adequate organ function; key exclusions include pregnancy, active HIV/HBV/HCV infection, significant heart problems or QT prolongation, active brain metastases, and recent systemic anticancer therapy or conflicting medications. Status: COMPLETED. Sponsor: TransThera Sciences (Nanjing), Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer is being studied. Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative +64 • Eligibility: Inclusion Criteria: * Newly diagnosed patients for the following conditions * Colon cancer stage III and IV * Rectal cancer stage II, III, IV * Glioblastoma multiforme (brain)…. Goal: This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adding dasatinib to the FOLFOX chemotherapy regimen (with or without bevacizumab) to see if it can prevent oxaliplatin-related nerve damage in people with metastatic gastrointestinal cancers. - It is for adults with colon, rectal, or other GI cancers who are candidates for mFOLFOX6, and it uses a dose-escalation design to find the recommended phase 2 dose and assess safety. - The study also looks at how dasatinib might change the way oxaliplatin and 5-FU behave in the body, and vice versa. - Eligible participants must meet health and lab criteria; those who recently received other investigational drugs, have GI absorption issues, use strong OCT2/CYP3A4 inhibitors, are on certain targeted therapies like cetuximab or panitumumab, have uncontrolled illness, or are breastfeeding may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer is being studied. Conditions: Neoplasms • Eligibility: Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid…. Goal: Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer Phase/Status/Sponsor: Unknown phase; COMPLETED; Vincerx Pharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer is being studied. Conditions: Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 +2 • Eligibility: Inclusion Criteria: * Pathologically confirmed metastatic or unresectable cholangiocarcinoma or gallbladder carcinoma (GBC), having received at least 1 prior line of systemic therapy, and received no more than…. Goal: This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery (unresectable) or gallbladder cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene is being studied. Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification +41 • Eligibility: Inclusion Criteria: Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male…. Goal: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. Phase/Status/Sponsor: Unknown phase; COMPLETED; Klus Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested TAS-102 (trifluridine/tipiracil) in people with advanced biliary tract cancers that have spread. - Participants had at least one prior systemic therapy and measurable disease with an ECOG performance status of 0 or 1. - The main goal was to determine if TAS-102 could improve progression-free survival at 16 weeks, with secondary goals including safety, overall response rate, and overall survival. - The study also explored biomarkers like circulating tumor cells (CTCs) and cell-free DNA (cfDNA) to see if they relate to prognosis or response, and whether tumor mutations affect outcomes. - The trial has completed; key exclusions included pregnancy, uncontrolled illnesses, HIV on antiretroviral therapy, and recent anticancer therapy or investigational agents.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether adjusting the irinotecan dose based on a patient’s UGT1A1 genetic type can improve safety for the FOLFIRABRAX chemotherapy regimen in advanced gastrointestinal cancers. - It includes patients with metastatic or locally advanced GI cancers, such as pancreatic, gastric, biliary tract cancers, gallbladder cancer, ampullary cancer, or cancers of unknown GI primary. - The primary goal is to determine the dose-limiting toxicity rate in cycle 1 across three UGT1A1 genotype groups (*1/*1, *1/*28, *28/*28) using genotype-guided dosing of irinotecan. - Secondary goals include measuring the cumulative dose of each drug given and the objective response rate by RECIST in patients with measurable disease. - Key exclusions include prior chemotherapy or radiation for any cancer, brain metastases, HIV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation is being studied. Conditions: Bladder Cancer • Eligibility: Inclusion Criteria: * The subjects who will undergo transurethral resection of the tumor after diagnosis of bladder cancer * Male or female aged 18 or over 18 years…. Goal: The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Center, Korea.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Programs To Support You During Chemotherapy is being studied. Conditions: Depression, Fatigue, Stage IIA Colorectal Cancer +18 • Eligibility: Inclusion Criteria: * Scheduled to receive first-line Fluorouracil (5FU)-based intravenous chemotherapy treatment for a gastrointestinal cancer (stages II-IV) * Have an Eastern Cooperative Oncology Group performance status of…. Goal: This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy. Possible mediators such as psychological stress, circadian disruption, and inflammation, will also be explored. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers is being studied. Conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7 +6 • Eligibility: Inclusion Criteria: * Patient must have histologically or cytologically confirmed intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer or may undergo a repeat biopsy for histologic confirmation if pre-existing…. Goal: This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with biliary cancers (which includes the gallbladder and bile ducts inside and outside the liver) that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies is being studied. Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary +37 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with…. Goal: This study is being done to determine the dose of a chemotherapy drug (irinotecan \[irinotecan hydrochloride\]) that can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs often used to treat gastrointestinal cancer, which consists of 5-FU (fluorouracil), leucovorin (leucovorin calcium), irinotecan and oxaliplatin and is known as "FOLFIRINOX". Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers is being studied. Conditions: Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter +81 • Eligibility: Inclusion Criteria: * Primary family caregivers of cancer patients with gastrointestinal (colorectal, pancreatic, gastric), gynecologic, urinary or lung cancers who are entering the City of Hope for treatment…. Goal: This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested the maximum tolerated dose of everolimus given with gemcitabine, and then with cisplatin added, in adults with unresectable solid tumors that did not respond to standard therapy. - It evaluated two- and three-drug regimens to assess safety and any signs of anti-tumor activity. - A small cohort explored cholangiocarcinoma or gallbladder cancer to gather pilot data. - Eligibility included histologically confirmed unresectable cancer refractory to standard therapy, adequate organ function, ECOG 0-2, and ability to consent and return for follow-up; major exclusions included prior everolimus, uncontrolled illness, active brain metastases, pregnancy, and certain cardiac or liver conditions. - Status: Completed; Sponsor: Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma is being studied. Conditions: Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia +6 • Eligibility: Inclusion Criteria: * Cytologically or pathologically confirmed gallbladder carcinoma or cholangiocarcinoma * No ampullary carcinoma * Locally advanced unresectable or distant metastatic disease * Measurable disease * Patients…. Goal: This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer is being studied. Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer +5 • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of 1 of the following: * Hepatocellular carcinoma (hepatoma) * Child-Pugh classification score ≤ 7 * Biliary tract carcinoma * Surgically unresectable…. Goal: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib ditosylate works in treating patients with unresectable liver or biliary tract cancer Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) is being studied. Conditions: Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer +85 • Eligibility: Inclusion Criteria: * Part I (closed to accrual as of 6/8/2007) * Histologically confirmed solid tumor that is metastatic or unresectable for which standard curative measures do not…. Goal: This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer is being studied. Conditions: Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer +8 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed hepatocellular carcinoma (HCC) or biliary carcinoma that is surgically unresectable; exception: for surgically unresectable HCC, a hypervascular mass on CT and…. Goal: Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib may interfere with the growth of cancer cells and slow the growth of the tumor. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tested the combination of interleukin-12 and trastuzumab in people with HER2/neu-overexpressing cancers that have not responded to prior treatment. It was a Phase I dose-escalation trial to find the highest IL-12 dose that could be given safely with trastuzumab and to assess safety. The trial also looked at immune effects, including tumor gene expression, natural killer cell activity, and serum interferon gamma levels. Participants needed measurable disease from HER2-overexpressing cancer and adequate organ function, with a life expectancy of at least 6 months. Exclusions included brain metastases, significant cardiovascular disease, pregnancy, HIV or hepatitis B infection, recent cancer therapies, and prior treatment with Herceptin; the study is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer is being studied. Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas +39 • Eligibility: Inclusion Criteria: * Histologically confirmed adenocarcinoma that failed standard curative options and for which no standard palliative options are required within the next 8weeks * Advanced or metastatic…. Goal: Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma is being studied. Conditions: Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder +7 • Eligibility: Inclusion Criteria: * Patients must have a cytologically or pathologically confirmed diagnosis of cholangiocarcinoma or gallbladder carcinoma * The pathologic confirmation of gallbladder or cholangiocarcinoma may be made…. Goal: This phase II trial is studying how well sorafenib works in treating patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion: * Patients must have a pathologically or cytologically confirmed carcinoma (except neuroendocrine) of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or gallbladder) that is not eligible for…. Goal: The purpose of this research study is to determine the safety and efficacy of CPI-613 (devimistat) in the treatment of advanced biliary tract cancer when used in combination with standard of care chemotherapy (gemcitabine plus cisplatin) compared to gemcitabine plus cisplatin alone. This research study has two parts: In the phase 1 portion of this study, patients will receive a combination of CPI-613 and standard of care chemotherapy. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Michigan Rogel Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers is being studied. Conditions: Solid Tumor, Lymphoma • Eligibility: Abreviated Inclusion Criteria 1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or * eligible to receive single-agent pembrolizumab as standard of care, or * eligible to receive single-agent…. Goal: This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies. Phase/Status/Sponsor: Unknown phase; COMPLETED; Trishula Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) is being studied. Conditions: Biliary Tract Carcinoma • Eligibility: Inclusion Criteria * Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer) * Has measurable disease based…. Goal: This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS). Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor +2 • Eligibility: Inclusion Criteria: * Signed informed consent * Subjects must be ≥ 18 years of age ( ≥ 20 years of age for Taiwan site) * Subject with advanced…. Goal: ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702. Phase/Status/Sponsor: Unknown phase; COMPLETED; Acepodia Biotech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) is being studied. Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma +13 • Eligibility: Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following:…. Goal: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) is being studied. Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer • Eligibility: Inclusion Criteria * Are participants with histologically or cytologically confirmed locally advanced or metastatic BTC. * Availability of tumor (primary or metastatic) archival material or fresh biopsies is…. Goal: The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S is being studied. Conditions: Astrocytoma, Brain Cancer, Brain Metastases +20 • Eligibility: Inclusion Criteria: 1. Male or female participants aged ≥18 years at the time of informed consent. 2. Adequate Bone Marrow Function 3. Adequate renal function 4. Adequate Liver…. Goal: This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Quadriga Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria for dose escalation and expansion phase: * Signed written informed consent * Male or female participants aged greater than or equal to 18 years * Participants…. Goal: This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Phase/Status/Sponsor: Unknown phase; COMPLETED; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas is being studied. Conditions: Biliary Tract Cancer • Eligibility: Inclusion Criteria: * Patient must have histologically or cytologically confirmed Biliary tract carcinomas including intrahepatic, hilar cholangiocarcinoma and gallbladder cancer without evident liver metastasis. * Patient must have…. Goal: This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary tract carcinomas, and to explore a better first-line treatment regimen for these patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Peking University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tested vandetanib alone, vandetanib plus gemcitabine, and placebo plus gemcitabine to see if these regimens can prolong progression-free survival in advanced biliary tract cancer. It enrolled adults with unresectable or metastatic biliary tract cancer who had not received systemic therapy for advanced disease (adjuvant chemotherapy allowed if finished more than 3 months earlier) and who had a good performance status. The trial aimed to learn whether these treatments improve progression-free survival by the end of the study. Key exclusions included prior systemic therapy for advanced disease, significant cardiovascular disease or QTc prolongation, and inadequate organ function.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tested whether adding sorafenib to the chemotherapy drugs gemcitabine and cisplatin helps adults with advanced biliary tract cancers (bile duct or gallbladder cancer) who have not yet received systemic therapy. - It is a phase 2 trial designed to learn what effects (good and bad) this combination has on the cancer and its safety. - Eligible participants are adults with biliary tract cancer that cannot be removed by surgery or has spread, and who have measurable disease; key exclusions include prior systemic chemotherapy (with limited adjuvant exceptions), brain metastases, HIV, pregnancy, and significant cardiovascular or infection problems. - The trial is complete.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor is being studied. Conditions: Febrile Neutropenia, Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Male or female adults (age \> / = 18 years) * Diagnosed with one of the following types and stages of tumors: stage III or…. Goal: This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for primary or secondary FN prophylaxis to better describe the patient population at risk for FN and treated prophylactically in physician's best clinical judgement with filgrastim biosimilar (EP2006), to describe prophylaxis patterns involving filgrastim biosimilar (EP2006), and to evaluate hematology levels and variability in hematological outcomes, impact on chemotherapy delivery, radiotherapy, surgery, and mortality. Additionally the study aims to identify patient cohorts who are vulnerable to poor response to FN prophylaxis and experience break-through episodes of FN, understand the differences between prophylaxis responders and non-responders, and describe the degree to which prophylaxis of FN is in congruence with guideline recommendations. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sandoz.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer is being studied. Conditions: Bladder Cancer • Eligibility: Inclusion Criteria: * Histologically proven locally advanced (T2-4,N0,M0 or Tany,N1-3,M0) urothelial carcinoma of the bladder and be candidates for cystectomy following chemotherapy. Tumor specimens must be available for…. Goal: Study participants will have been diagnosed with bladder cancer that has invaded the muscle wall of the bladder. Surgery is used to remove cancer when it is in the muscle of the bladder. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Michigan Rogel Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tested whether a multi-part treatment is feasible for people with resected cholangiocarcinoma, gallbladder, pancreatic, or ampullary cancers. It enrolled adults 18 years or older with biopsy-proven cancers removed with curative intent who had good performance status and met specific lab and health criteria. Eligible participants could not be pregnant and could not have had prior chemotherapy or radiation for this cancer (with limited exceptions for certain past cancers in long remission). The treatment plan started with induction chemotherapy using gemcitabine and docetaxel, followed by radiation with continuous infusion 5-FU, then consolidation gemcitabine/docetaxel, and the trial is completed, sponsored by Washington University School of Medicine as a feasibility Phase II study.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction is being studied. Conditions: Bile Duct Obstruction, Pancreatic Cancer, Gallbladder Cancer +1 • Eligibility: Inclusion Criteria: * 20 years of age or older * oral and written information given and informed consent obtained * clinical data in accordance with malignant bile duct…. Goal: The primary purpose is to compare patency of two different types of biliary metal stents, i.e. covered versus uncovered Nitinella metal stent. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Linkoeping.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma is being studied. Conditions: NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: * Male or female patients ≥18 years of age. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she…. Goal: The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR. Phase/Status/Sponsor: Unknown phase; TERMINATED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers is being studied. Conditions: Solid Organ Cancers • Eligibility: Inclusion Criteria: * Histologically-proven diagnosis of advanced (AJCC, 7th Edition: stage III or IV) or aggressive solid organ cancer. * Patients must provide written consent for a core…. Goal: The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; Andrew Lowy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized trial tested whether adding capecitabine to gemcitabine improves survival for biliary cancer that is locally advanced, unresectable, or metastatic. It is for adults with biliary tract cancers (such as cholangiocarcinoma or gallbladder cancer) who have adequate organ function and a reasonable life expectancy. Participants were assigned to gemcitabine plus capecitabine versus gemcitabine alone to learn about overall survival and other outcomes like progression-free survival, response rate, quality of life, and toxicity. Key exclusions included no CNS metastases, no ampullary carcinomas, and no other active cancers or major unsafe medical conditions; prior chemotherapy for advanced disease was allowed only under specific circumstances. The study is terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC is being studied. Conditions: Non-muscle Invasive Bladder Cancer (NMIBC) • Eligibility: Inclusion Criteria: 1. Male or female patients ≥18 years of age at the time of consent 2. Patient must have been adequately treated with BCG defined as at…. Goal: This study, BC-819-18-204, is a Phase 2, open-label, monotherapy, single-arm, multicenter clinical trial of BC-819 (inodiftagene vixteplasmid) in patients with NMIBC adequately treated with Bacillus Calmette-Guerin (BCG) whose disease is BCG unresponsive according to the US Food and Drug Administration (FDA) guidance. Phase/Status/Sponsor: Unknown phase; TERMINATED; Anchiano Therapeutics Israel Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.